Clinical Experience with Amrinone in Patients with Advanced Congestive Heart Failure

EVLIN L. KINNEY, BRIAN CARLIN, James Ballard, JOHN M. BURKS, WILLIAM F. HALLAHAN, Robert Zelis

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Abstract: To examine the efficacy of chronic amrinone therapy, the drug was administered to 12 patients with advanced congestive heart failure on average for 27.9 days. The majority of patients had a persistent increase in cardiac index and a persistent decrease in systemic vascular resistance. A decrease in pulmonary arterial diastolic pressure was observed after oral amrinone administration in three patients. However, changes in pulmonary arterial pressure were not consistent in response to intravenous administration of the drug. Thrombocytopenia occurred in four patients, hypogeusia was noted by three patients, and dysosmia developed in two patients. The cumulative survival of the amrinone patients was significantly poorer than that of a second group of patients with congestive heart failure having similar symptoms. These findings indicate that there is a subset of patients with congestive heart failure who do not benefit from chronic amrinone administration and that in such patients its use (especially when given concomitantly with potentially toxic and hypotentsive drugs) should be extremely guarded. 1982 American College of Clinical Pharmacology

Original languageEnglish (US)
Pages (from-to)433-440
Number of pages8
JournalThe Journal of Clinical Pharmacology
Volume22
Issue number10
DOIs
StatePublished - Jan 1 1982

Fingerprint

Amrinone
Heart Failure
Arterial Pressure
Ageusia
Olfaction Disorders
Lung
Clinical Pharmacology
Poisons
Thrombocytopenia
Pharmaceutical Preparations
Intravenous Administration
Vascular Resistance
Oral Administration

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

KINNEY, EVLIN L. ; CARLIN, BRIAN ; Ballard, James ; BURKS, JOHN M. ; HALLAHAN, WILLIAM F. ; Zelis, Robert. / Clinical Experience with Amrinone in Patients with Advanced Congestive Heart Failure. In: The Journal of Clinical Pharmacology. 1982 ; Vol. 22, No. 10. pp. 433-440.
@article{9de885c235c74e2c8538e6783afcde57,
title = "Clinical Experience with Amrinone in Patients with Advanced Congestive Heart Failure",
abstract = "Abstract: To examine the efficacy of chronic amrinone therapy, the drug was administered to 12 patients with advanced congestive heart failure on average for 27.9 days. The majority of patients had a persistent increase in cardiac index and a persistent decrease in systemic vascular resistance. A decrease in pulmonary arterial diastolic pressure was observed after oral amrinone administration in three patients. However, changes in pulmonary arterial pressure were not consistent in response to intravenous administration of the drug. Thrombocytopenia occurred in four patients, hypogeusia was noted by three patients, and dysosmia developed in two patients. The cumulative survival of the amrinone patients was significantly poorer than that of a second group of patients with congestive heart failure having similar symptoms. These findings indicate that there is a subset of patients with congestive heart failure who do not benefit from chronic amrinone administration and that in such patients its use (especially when given concomitantly with potentially toxic and hypotentsive drugs) should be extremely guarded. 1982 American College of Clinical Pharmacology",
author = "KINNEY, {EVLIN L.} and BRIAN CARLIN and James Ballard and BURKS, {JOHN M.} and HALLAHAN, {WILLIAM F.} and Robert Zelis",
year = "1982",
month = "1",
day = "1",
doi = "10.1002/j.1552-4604.1982.tb02632.x",
language = "English (US)",
volume = "22",
pages = "433--440",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",
number = "10",

}

Clinical Experience with Amrinone in Patients with Advanced Congestive Heart Failure. / KINNEY, EVLIN L.; CARLIN, BRIAN; Ballard, James; BURKS, JOHN M.; HALLAHAN, WILLIAM F.; Zelis, Robert.

In: The Journal of Clinical Pharmacology, Vol. 22, No. 10, 01.01.1982, p. 433-440.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinical Experience with Amrinone in Patients with Advanced Congestive Heart Failure

AU - KINNEY, EVLIN L.

AU - CARLIN, BRIAN

AU - Ballard, James

AU - BURKS, JOHN M.

AU - HALLAHAN, WILLIAM F.

AU - Zelis, Robert

PY - 1982/1/1

Y1 - 1982/1/1

N2 - Abstract: To examine the efficacy of chronic amrinone therapy, the drug was administered to 12 patients with advanced congestive heart failure on average for 27.9 days. The majority of patients had a persistent increase in cardiac index and a persistent decrease in systemic vascular resistance. A decrease in pulmonary arterial diastolic pressure was observed after oral amrinone administration in three patients. However, changes in pulmonary arterial pressure were not consistent in response to intravenous administration of the drug. Thrombocytopenia occurred in four patients, hypogeusia was noted by three patients, and dysosmia developed in two patients. The cumulative survival of the amrinone patients was significantly poorer than that of a second group of patients with congestive heart failure having similar symptoms. These findings indicate that there is a subset of patients with congestive heart failure who do not benefit from chronic amrinone administration and that in such patients its use (especially when given concomitantly with potentially toxic and hypotentsive drugs) should be extremely guarded. 1982 American College of Clinical Pharmacology

AB - Abstract: To examine the efficacy of chronic amrinone therapy, the drug was administered to 12 patients with advanced congestive heart failure on average for 27.9 days. The majority of patients had a persistent increase in cardiac index and a persistent decrease in systemic vascular resistance. A decrease in pulmonary arterial diastolic pressure was observed after oral amrinone administration in three patients. However, changes in pulmonary arterial pressure were not consistent in response to intravenous administration of the drug. Thrombocytopenia occurred in four patients, hypogeusia was noted by three patients, and dysosmia developed in two patients. The cumulative survival of the amrinone patients was significantly poorer than that of a second group of patients with congestive heart failure having similar symptoms. These findings indicate that there is a subset of patients with congestive heart failure who do not benefit from chronic amrinone administration and that in such patients its use (especially when given concomitantly with potentially toxic and hypotentsive drugs) should be extremely guarded. 1982 American College of Clinical Pharmacology

UR - http://www.scopus.com/inward/record.url?scp=0020431947&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020431947&partnerID=8YFLogxK

U2 - 10.1002/j.1552-4604.1982.tb02632.x

DO - 10.1002/j.1552-4604.1982.tb02632.x

M3 - Article

VL - 22

SP - 433

EP - 440

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 10

ER -